The changing landscape of diabetes management is witnessing a significant shift, driven by innovative incretin-based therapies. Currently, semaglutide has achieved considerable traction, but competing medications like https://idafcqk492782.blogdigy.com/the-future-of-diabetes-comparing-tirzepatide-semaglutide-retatrutide-and-cagrilintide-66461815